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Background: Alternative splicing contributes to the diversity of the proteome, and provides the cell with an
important additional layer of regulation of gene expression. Among the many RNA binding proteins that regulate
alternative splicing pathways are the Muscleblind-like (MBNL) proteins. MBNL proteins bind YGCY motifs in RNA via
four CCCH zinc fingers arranged in two tandem arrays, and play a crucial role in the transition from embryonic to
adult muscle splicing patterns, deregulation of which leads to Myotonic Dystrophy. Like many other RNA binding
proteins, MBNL proteins can act as both activators or repressors of different splicing events.
Results: We used targeted point mutations to interfere with the RNA binding of MBNL1 zinc fingers individually
and in combination. The effects of the mutations were tested in assays for splicing repression and activation,
including overexpression, complementation of siRNA-mediated knockdown, and artificial tethering using MS2 coat
protein. Mutations were tested in the context of both full length MBNL1 as well as a series of truncation mutants.
Individual mutations within full length MBNL1 had little effect, but mutations in ZF1 and 2 combined were more
detrimental than those in ZF 3 and 4, upon splicing activation, repression and RNA binding. Activation and repression
both required linker sequences between ZF2 and 3, but activation was more sensitive to loss of linker sequences.
Conclusions: Our results highlight the importance of RNA binding by MBNL ZF domains 1 and 2 for splicing
regulatory activity, even when the protein is artificially recruited to its regulatory location on target RNAs. However,
RNA binding is not sufficient for activity; additional regions between ZF 2 and 3 are also essential. Activation and
repression show differential sensitivity to truncation of this linker region, suggesting interactions with different sets of
cofactors for the two types of activity.Background
Pre-mRNA splicing is a critical part of mRNA matur-
ation, and alternative splicing is a well established
method of generating diversity and exerting control over
the proteome. It is now recognised that the vast majority
of transcripts are alternatively spliced, allowing produc-
tion of many protein isoforms from a single gene (for re-
view see [1]). The process is controlled so that certain
isoforms are restricted to specific cell types, develop-
mental stages, or conditions [2,3]. Alternative splicing is
controlled in large part by a variety of a protein factors
which can positively or negatively influence splicing at
adjacent splice sites. Early investigations suggested that
proteins of the SR family generally act as splicing activa-
tors, while proteins of the hnRNP family typically act as* Correspondence: cwjs1@cam.ac.uk
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stated.repressors. More recent global analyses of the activities of
RNA binding proteins has indicated that many of them
show both activator or repressor activity, depending on
the site at which they bind to the target pre-mRNA [4].
Loss of regulation of alternative splicing can lead to a
variety of diseases, including Myotonic Dystrophy (DM1),
which is caused by expansions of CUG repeats, which
bind and sequester muscleblind like (MBNL) proteins [5].
MBNL proteins normally control the transition from em-
bryonic to adult isoforms of a sub-set of muscle-specific
proteins in heart and skeletal muscle cells [6-8]. In DM1,
embryonic isoforms of important muscle proteins are
expressed, which causes the various clinical symptoms
[9,10]. For example, myotonia is casued by deregulation of
a MBNL-controlled splicing event in the skeletal muscle
chloride channel (CLCN1) [11].
MBNL is a four zinc-finger (ZF) containing protein (of
the type CX7CX4-6CX3H). The ZF domains are arrangedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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tein (Figure 1A). The RNA binding faces in each dido-
main are arranged back-to-back, creating a predicted
anti-parallel alignment of RNA binding to adjacent ZFs
[12,13]. SELEX experiments have determined the opti-
mal MBNL binding sequence to consist of multiple
YGCY motifs [14], explaining the binding to CUG ex-
pansions. By using U-tracts with two GC steps and ma-
nipulating the spacing between them, it has been shown
that MBNL can bind the two sites with as little as a 1 nt
spacer separating them, or in a second binding conform-
ation with a spacer of around 17 nt [15], suggesting mul-
tiple modes of RNA-protein interaction. The published
crystal structures of MBNL1 ZF domains [13] shows
how the two domains in the ZF34 tandem array interact
with the RNA. Key aromatic residues in ZF3 and 4
(F202 and Y236) intercalate between the bases of the
GC step, while specific hydrogen bonds from the GC
bases to side chains in the protein partly explain the
binding specificity of MBNL-1.
The MBNL1 gene is comprised of 12 exons, 10 of
them protein coding, with the ZFs encoded by exons 2–6.
Extensive alternative splicing of exons encoding the
linker between ZFs 2 and 3, and the C-terminal end of
the protein leads to multiple functionally distinct protein
isoforms [16]. Structure-function analyses of MBNL1
and 3 have been performed by generating N- and C–
terminal truncations and analysing the effect on splicing
regulation. In this analysis, the regions of MBNL re-
quired for splicing repression and activation differed.
Activation required the entire linker sequence between
ZF 2 and 3, while repression required only a small
N-terminal portion of the linker [17]. A second structure-
function analysis involved targeted mutations to impair
RNA binding by the different ZF domains, and analysis of
the consequences upon MBNL-repressed and MBNL-
activated events [18]. Although activity is usually linked to
RNA binding, there is a subset of events where the affinity
of MBNL for the RNA is not correlated with activity.
Artificial recruitment systems have been used to great
effect to analyze the function of splicing factors and
other RNA binding proteins. This method involves ex-
pressing the protein of interest as a fusion with a heter-
ologous RNA binding protein, such as MS2 coat-protein,
and replacing the normal binding site on the target RNA
with an MS2 binding site. This circumvents the normal
mode of RNA binding and allows the dissection of spli-
cing activator or repressor domains. This approach has
been used to investigate SR proteins [19] hnRNP and
other RNA binding proteins including hnRNP A1 [20],
PTB [21], MBNL1 [22], RbFOX [23] and hnRNPL [24].
Here we use targeted mutations to disrupt RNA bind-
ing by individual ZF domains of MBNL1 combined with
larger deletions to analyse the splicing activation andrepression function of MBNL1 in both MS2-tethered and
non-tethered splicing assays. We find that full length
MBNL1 is remarkably tolerant of mutation to individual
ZFs or pairs of ZFs in a simple cotransfection assay. How-
ever, in MS2 tethering assays of the N-terminal part of
MBNL1 containing the four ZF domains, mutation of ZF3
and 4 has no effect on splicing repression, but mutation of
ZF1 and 2 is highly deleterious. In contrast, for activation
no mutations or pairs of mutations drastically reduce ac-
tivity. When artificially recruited, only the first two zinc
fingers plus a small N-terminal portion of the linker se-
quence between ZF 2 and 3 is required for repression,
whereas for activation the whole linker sequence is needed
even though this region plays no part in RNA binding. For
both activation or repression, disruption of RNA binding
by ZFs 1 and 2 is highly deleterious for activity. Our
results further highlight the distinct requirements of
different regions of MBNL1 for splicing repression and
activation.
Results
Effect of MBNL RNA binding mutations on MBNL-regulated
splicing events
Based on high resolution structures of the TIS11d [25]
and MBNL proteins [12,13] we designed point mutations
in each MBNL zinc finger that would disrupt RNA bind-
ing, without severely altering the overall fold and struc-
ture of the domain. We targeted conserved aromatic
residues F36, Y68, F202 and Y236 in ZF 1–4 respect-
ively, and mutated them to alanine (Figure 1A). The mu-
tations were introduced individually, in combinations in
the two di-domains (MBNL-FL-M12 and -M34) and into
all four ZF domains simultaneously. Similar mutations
have since been reported by others [18,26]. In order to
confirm that the mutations disrupt RNA binding, re-
combinant MBNL1 aa 2–253 was produced with all four
zinc fingers mutated and compared to wildtype protein
in UV crosslinking assays. While the wild-type cross-
linked to the RNA the mutant did not (Figure 1B, lower
panel).
We next tested the effects of the MBNL ZF mutants
in assays for splicing repression and splicing activation
by MBNL1 in HeLa cells. To test splicing repressor ac-
tivity we used a Tpm1 minigene with a point mutation
of the branch point of exon 3, which increases exon 3
skipping in HeLa cells [22,27]. This minigene responds
modestly to simple overexpression of MBNL1. However,
upon knockdown of MBNL1 (Figure 1E) exon skipping is
reduced substantially (from 35 to 13%, Figure 1C, lanes 1,
2); complementation with overexpressed MBNL1 restores
exon skipping to 53% (Figure 1C, lane 10). As a model
MBNL-activated exon we used a minigene construct
containing a Vldlr exon flanked by globin exons [10],
which responds to MBNL1 overexpression by increasing
AZF1 M1 =  F36A
ZF2 M2 = Y68A
ZF3 M3 =  F202A
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Figure 1 Effects of RNA binding mutations on MBNL1 splicing activity. A. Schematic representation of MBNL1. Zinc fingers are shown in black,
the C-terminus in purple. Amino acid positions of deletion boundaries mutants and ZF domain inactivating mutations are indicated. The 382 aa MBNL1
isoform lacks sequences corresponding to exons 7 and 9. B. Comparison of wild type MBNL-N and MBNL-N-M1234 UV crosslinking to RNA. Upper panel,
Coomassie blue stained gel; lower panel UV crosslinking. RNA used for crosslinking encompassed Tpm1 exon 3 and both upstream and downstream
MBNL elements. The identity of crosslinked MBNL (lanes 1-3) was established by immunoprecipitation with anti-MBNL1 (lane 9) but not anti-GST anti-
bodies (lane 8). The asterisked band is a contaminant that was not immunoprecipitated by anti-MBNL1; it does not correspond to the higher molecular
weight contaminant in the Coomassie stained samples of mutant protein (lanes 4–6). C. Effects of MBNL1 knockdown and overexpression upon Tpm1
splicing in HeLa cells. The cartoon depicts the ΔBP minigene; the U and D MBNL binding elements and P3 and DY pyrimidine tracts are indicated. The
minigene was co-transfected with control (C2, lane 1) or MBNL1 siRNAs (lanes 2–10), and with wild-type MBNL1 (lane 10) or MBNL1 mutants in the
indicated ZF domains (lanes 3–9). Values significantly different from FL wild type MBNL1: **, P < 0.01; *** P < 0.001; ns, not significant. Values for the
M1234 mutant are statistically significant, but lack of protein expression (panel F) prevents meaningful conclusions from being drawn. D. Effects of
MBNL1 overexpression upon Vldlr splicing in HeLa cells. The cartoon depicts the Vldlr minigene; the MBNL1 binding site is indicated by the yellow
diamond. The minigene was transfected alone (lane 1), with wild-type MBNL1 (lane 9) or mutants in ZF domains (lanes 2–8). E. Western blot of MBNL1
in mock transfected, control(C2) or MBNL1 siRNA treated cells. F. Anti-FLAG western blot showing expression of MBNL1 constructs from panels C and D.
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Note that in order to facilitate comparison of the repres-
sor and activator activities of MBNL1 mutants, we referthroughout to percentage exon skipping of the repressed
Tpm1 exon but percentage exon inclusion of the acti-
vated Vldlr exon.
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single point-mutants had moderately reduced repressor
activity, producing exon skipping levels of 32-44%
(Figure 1C, lanes 3–6), as did the combined ZNF 3 and
4 mutant (lane 8). Surprisingly, the mutant with com-
bined mutations in ZF 1 and 2 was as active as wild type
MBNL1 (lane 7), despite being expressed at similar
levels to the other constructs (Figure 1F). The mutant
with all four ZF domains impaired showed no activity
(Figure 1C, lanes 2 and 9). However, this mutant was
consistently expressed at lower levels than the other
constructs (Figure 1F), preventing strong conclusions
about its activity. We noted that the MBNL proteins
with mutations in ZF1 (MBNL-FL-M1 and MBNL-FL-
M12) consistently showed the presence of additional
slower migrating bands that were detected with FLAG
antibodies (Figure 1F). We do not know the explanation
for these additional bands, or whether they represent an
active fraction of protein. It is therefore possible that higher
total levels of active proteins with the M1 mutation might
partially mask loss of activity induced by the mutation.
Mutations in ZF1 or 2 had no significant effect upon the
ability of MBNL1 to activate Vldlr splicing (Figure 1D,
lanes 2,3,9), while mutations in ZF 3 or 4 individually
caused a small but significant increase in activity (lanes
4,5). Double mutations of ZF 3 and 4 or 1 and 2 combined
were also without significant effect (lanes 6,7), although
the 12 mutant was significantly less active than 34 (P <
0.05). Only the quadruple ZF1-4 mutant showed signifi-
cantly lower activity than WT MBNL1 (lane 8), but again
no firm conclusions could be drawn due to the much
lower expression levels of this mutant (Figure 1F).
Taken together, the preceding data indicated that both
repressor and activator activities of MBNL1 are remark-
ably tolerant of mutations that impair RNA binding of
individual ZF domains, and even mutations of both ZFs
within a didomain have limited effects.
MS2 tethering of MBNL1 activation and repression domains
We next compared the activities of deletion mutants of
MBNL1 in simple cotransfection and tethered function
assays (Figure 2). Consistent with previous data [22] in
the knockdown/complementation assay with the Tpm1
reporter, the N-terminal region of MBNL1 (aa 2–253)
had similar repressor activity to the full length protein
(Figure 2B, lanes 3,5). In contrast, a C-terminal fragment
of MBNL1 (aa 239–382) had no activity (Figure 2B, lane 4).
Similar effects were seen with the Vldlr reporter; the N-
terminal fragment had indistinguishable activity to full
length MBNL1 (Figure 2C, lanes 2,4), while the C-terminal
fragment was devoid of activator activity (lane 3), despite
being expressed to similar levels (Figure 2A).
As reported previously [22] replacement of the down-
stream MBNL1 binding element in Tpm1 with a bindingsite for MS2 coat protein led to a ~3-fold decrease in
exon skipping (Figure 2E, lanes 1,2). Addition of MS2
coat protein had little effect (lane 6), while fusion
proteins of MS2 with full length MBNL1 or just the
N-terminal region led to high levels of exon skipping
(lanes 3,4). In contrast, the C-terminal region of MBNL1
fused to MS2 had a significant, but much more modest
effect than full length MBNL1-MS2 (lane 5). Replace-
ment of the reported MBNL1 binding site containing
two GC motifs downstream of the Vldlr exon with a sin-
gle MS2 site reduced exon inclusion from 14% to 2%
(Figure 2F, lanes 1,2), consistent with the activity of this
element as an MBNL-dependent splicing enhancer in
mouse embryonic fibroblasts [10]. Co-transfection with
MS2 protein had no effect (lane 6), while full length
MBNL1-MS2 restored exon inclusion levels (lane 3). As
in the repression assay, the N-terminal of MBNL1-MS2
had full activity, while the C-terminal region had partial
activity (lanes 4,5). These data indicate that the N-
terminal region of MBNL1 has full activity in simple
co-transfection and artificial tethering repression and en-
hancing assays, while the C-terminal region was inactive
in simple cotransfections and had partial activity in teth-
ered assays.
In the artificial tethering assay, the MS2 domain serves
to recruit the fusion protein to the regulated RNA, pre-
sumably bypassing the RNA-binding function of at least
some of the ZF domains. To explore this issue we intro-
duced the RNA binding mutations into the ZF domains of
the MBNL-N-MS2 construct (Figure 3). Tethering of the
WT MBNL-N-MS2 downstream of Tpm1 exon 3
increased exon skipping from 20% (lanes 1,10) to 71%
(lane 9). Individual mutations in ZF1-4 or combined mu-
tations in ZF3 and 4 had no effect on activity (lanes 2–5, 7).
However, combined mutations in ZF1 and 2 drastically re-
duced activity (lane 6), even though the protein was
expressed (Figure 3B). Indeed, exon skipping levels in the
presence of the ZF12 mutant were not significantly differ-
ent from MS2 alone or no cotransfection (lane 6, com-
pared to lanes 1 or 10). The quadruple mutant in ZF1-4
was also inactive, but again the protein was expressed at
very low levels (lane 8 and Figure 3B). The complete loss
of activity upon ZF12 mutation in the tethered repressor
assay is in stark contrast to the more modest effects in the
simple cotransfection assay (Figures 1C and 3A). In the
tethered activation assay the single mutations in ZF1, 3
and 4, and the combined mutation of ZF3 and 4 led to a
modest but significant increase in activity while the ZF2
mutation was without effect (Figure 3C, lanes 2–5,7 com-
pared to 9). Only the dual ZF12 mutant showed decreased
activity (lane 6) but the effect was modest compared to
the loss of repressor activity.
MBNL1 is thought to dimerize through its C terminus
[16,28]. However, the crystal structure of ZF34 revealed a
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Figure 2 Activity of MBNL1 N and C-terminal domains in splicing repression and activation. A. Schematic of the regions of MBNL1 used in
the experiments in this figure (top). Lower panel, anti-FLAG western blot showing expression of MBNL proteins. B. The Tpm1 ΔBP minigene was
co-transfected with control (C2, lane 1) or MBNL1 targeting siRNAs (lanes 2–5). In addition, full-length MBNL1 (lane 5) or the MBNL1 N- or
C-terminal domains (lanes 3–4) were cotransfected along with the MBNL1 siRNA. C. The Vldlr minigene was transfected alone (lane 1) or with full-
length MBNL1 (lane 4) or the MBNL1 N- or C-terminal domains (lanes 2, 3). D. Anti-MS2 western blot of HeLa cells transfected with MS2 alone,
lane 6, or MBNL1-MS2 fusion proteins: full length, lane 5; MBNL1 C-terminus, lane 4, MBNL1 N-terminus, lane 3; mock transfections lanes 1, 2.
E. Schematic of the Tpm1 ΔBP DMS2 minigene in which the downstream MBNL site is replaced by a pair of MS2 hairpins (upper panel). Lower
panel, RT-PCR of HeLa cells transfected with Tpm1 ΔBP (lane 1) or Tpm1 ΔBP DMS2 (lanes 2–6). Cotransfections with MS2 alone (lane 6) or the
indicated MBNL1-MS2 fusion proteins (lanes 3–5). F. Schematic of the Vldlr-MS2 minigene in which the downstream MBNL site is replaced by an
MS2 hairpin (upper panel). Lower panel, RT-PCR of HeLa cells transfected with Vldlr (lane 1) or Vldlr-MS2 (lanes 2–6). Cotransfections with MS2
alone (lane 6) or the indicated MBNL1-MS2 fusion proteins (lanes 3–5).
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ZF4 in one subunit, with the reverse face of ZF4 in the
other subunit [13]. We tested the effects of individual orcombined mutations in Tyrosine 224 (Y224S) and Glu-
tamine 244 (Q244N), which are predicted to impair the
potential dimerization contact, but not RNA binding



































































































































































Figure 3 Effects of RNA binding mutations on tethered MBNL1 repressor and activator function. A. The Tpm1 ΔBP DMS2 minigene was
transfected alone (lane 1), or co-transfected with MS2 (lane 10), or MS2 fused to the N-terminal (aa 2–253) of MBNL1 (lanes 2–9). The MBNL-MS2
fusion proteins were WT (lane 9) or had the indicated ZF mutations (lanes 2–8). The horizontal dashed lines indicate the activity of the wild type
N-MS2 (lane 9). Values significantly different from wild type N-MS2 in panels A and C: **, P < 0.01; *** P < 0.001; ns, not significant. Note that
although the values for the M1234 mutant in lane 8 of panels A and C are statistically significant, the lack of protein expression of the M1234
mutant (panel B) means that meaningful conclusions cannot be drawn. B. Anti-MS2 western blot of MBNL-MS2 fusion proteins used in panels A
and C. C. The Vldlr MS2 minigene was transfected alone (lane 1), or co-transfected with MS2 (lane 10), or MS2 fused to the N-terminal (aa 2–253)
of MBNL1 (lanes 2–9). The MBNL-MS2 fusion proteins were WT (lane 9) or had the indicated ZF mutations (lanes 2–8). The horizontal dashed lines
indicate the activity of the wild type N-MS2 (lane 9).
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ered repressor (4C) or activator (Figure 4D) activities of
MBNL-N-MS2, or on the direct activation of Vldlr by
full length MBNL1 (Figure 4B). These results suggest
that the observed crystal contact between MBNL1
subunits is not important for MBNL1 function.
MBNL1 binding to RNA species from MBNL-regulated exons
Having investigated the role of the MBNL1 ZF domains
in splicing repression and activation, we next tested the
binding of MBNL1-N to RNAs containing the MBNL
binding elements of Vldlr and Tpm1 by electrophoretic
mobility shift assay (Figure 5). We compared binding ofWT MBNL1-N with the mutants in ZF12 (M12) and
ZF34 (M34). WT MBNL1 bound to the Vldlr and up-
stream Tpm1 elements, Tpm1 URE, with Kd in the 0.5 –
1 nM range, while binding to the downstream Tpm1
element Tpm1 Dugc, was approximately 10-fold lower af-
finity (Figure 5A, Kd 25–50 nM). With the Vldlr RNA a
second binding event was also observed with a much
lower affinity; we observed no additional binding events to
either of the Tpm1 elements, even though their length is
sufficient to accommodate multiple binding sites [15].
Mutation of ZF34 reduced the affinity of binding to all
three RNAs by about ~20-fold (Figure 5B). In contrast,




































































































































































Lane: 1 2 3 4 5 6
Figure 4 Mutations in a potential dimerization contact in ZF4 have no effect. A. Schematic of the potential ZF4-ZF4 dimerization contact
identified in MBNL1 crystal structures. The RNA binding face of one ZF4 unit interacts with the opposite face of the second ZF4 unit. Mutation of
Y224 and Q244 is predicted to interfere with the potential protein-protein interaction, but not with RNA binding by ZF4. B. The Vldlr minigene
was transfected alone (lane 1), or with MBNL1 FL (lanes 2–7). The MBNL1 was WT (lane 7) or carried the indicated ZF4 mutations. C. The Tpm1
ΔBP DMS2 minigene was transfected alone (lane 1), or co-transfected with MS2 (lane 7), or MS2 fused to the N-terminal (aa 2–253) of MBNL1
(lanes 2–6). The MBNL-MS2 fusion proteins were WT (lane 6) or had the indicated ZF4 mutations (lanes 2–5). D. The Vldlr MS2 minigene was trans-
fected alone (lane 1), or co-transfected with MS2 (lane 6), or MS2 fused to the N-terminal (aa 2–253) of MBNL1 (lanes 2–5). The MBNL-MS2 fusion pro-
teins had the indicated ZF mutations (lanes 2–5). E. Anti-MS2 western blot of MBNL1-MS2 fusion proteins corresponding to lanes 1–6 of panel C.
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http://www.biomedcentral.com/1471-2199/14/29stable complexes were observed on any of the RNAs, even
when up to 2 μM MBNL protein was used (Figure 5C).
Thus, the N-terminal ZF12 domains are more important
for both binding to Tpm1 and Vldlr RNAs, as well as for
tethered activity.MS2 tethering of MBNL1 truncations
To analyse further the roles of the pairs of tandem zinc
fingers we tested a series of deletion mutations based on
MBNL-N-MS2. These included a C-terminal deletion
series (previously tested on Tpm1 [22]), a natural deletion
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Figure 5 MBNL binding to Vldlr and Tpm1 RNAs. RNA binding was assessed by native gel electrophoretic mobility shift assay. RNAs are the
MBNL-responsive element from Vldlr (left panels), the upstream MBNL binding site of Tpm1 exon 3 (middle panels), and the downstream MBNL
binding site of Tpm1 exon 3 (right panels). Recombinant proteins used were: A, MBNL-N, the wild-type MBNL construct comprising amino acids
2–253 and containing all four zinc fingers, B, MBNL-N-M34, with ZF34 mutated, C, MBNL-N-M12 with ZF12 mutated, D, MBNL-2-116 E, MBNL-2-91
F, MBNL-2-72. Increasing protein concentrations are indicated by the wedges above each panel. Protein concentrations were 0, 0.1, 0.5, 1, 2, 5, 10,
25, 50, 100, 250, 500 nM for panel A, 0, 0.1, 0.5, 1, 2, 5, 10, 25, 50, 100, 250, 1000 nM for panels D and E, and 0, 1, 2, 5, 10, 25, 50, 100, 250, 500,
1000, 2000 nM for panels B, C and F. Estimated Kd’s are indicated in the lower right corner of each panel.
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183), an N-terminal deletion series, and the linker alone.
The linker sequence is predicted to be unstructured, but
parts of it are highly conserved and have been shown pre-
viously to have a role in MBNL activities [17,18,22]. We
expressed these proteins as MS2-fusions (Figure 6B) and
analysed their activity when recruited to either thedownstream Tpm1 (repressed, Figure 6C) or Vldlr (acti-
vated, Figure 6D) sites.
When recruited downstream of the MBNL-repressed
Tpm1 exon 3 (the Tpm1-ΔbpDMS2 minigene) zinc fin-
gers 3 and 4 and the C-terminal part of the linker could
be removed individually or in combination with no effect























































































































































































































































































































Figure 6 Comparison of MBNL1 deletions and point mutations upon tethered repression and activation. A. Schematic of the full-length
MBNL1-MS2 construct with boundaries of various deletions indicated. B. Anti-MS2 western blot of proteins used in subsequent panels. C. The
Tpm1 ΔBP DMS2 minigene was transfected alone (lane 1), or co-transfected with MS2 (lane 17), MS2 fused to full-length MBNL1 (lane 2), or the
various deletion constructs indicated by the amino acid coordinates. Δ116-183 (lane 4) is a natural MBNL1 isoform resulting from exon skipping.
Lanes 14–16 show the effects of the ZF1 and 2 mutations in the context of the 2-116-MS2 deletion mutant. In the experiment shown, the 2-253-
MS2 was not expressed (lane 3); in other experiments (e.g. Figure 2E) its activity was similar to FL-MBNL1. The asterisked band is an artefactual
band that does not appear in most experiments. Values significantly different from wild type MBNL1-FL-MS2 in panels C and D: **, P < 0.01;
*** P < 0.001; ns, not significant. D. The Vldlr-MS2 minigene was co-transfected with the same effectors as panel C. E. Comparison of effects of
mutations in panels C and D. The histogram indicates “% activity” for each of the MBNL1 constructs with the Tpm1 (green bars) and Vldlr (red
bars) substrates. The values shown are relative to the activity of FL-MBNL1-MS2. 100% activity is defined by the difference in exon skipping/inclusion in
the presence of FL-MBNL1-MS2 (upper horizontal line in histograms of panels C and D) and in the absence of co-transfection (lower horizontal lines).
The comparison shows more rapid decline of activation than repression with C-terminal deletions into the ZF23 linker.
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Complete removal of the linker sequence and an alpha-
helix of zinc finger 2 leaving only the first two zinc fin-
gers results in an inactive protein (lane 9). Despite the
importance of the linker region, when recruited alone ithad no activity above MS2 alone (lane 10, 17). Zinc fin-
gers 3 and 4 along with the complete preceding linker
region, or with just the C-terminal part of the linker,
were partially active (lanes 11,12). However, this activity
required the linker sequence as ZF34 alone were inactive
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the protein comprising amino acids 2–102, encompass-
ing the first two zinc fingers plus a third of the linker
sequence, constitutes a minimal repressor domain.
Introduction of RNA binding mutations into ZF1 or 2
individually drastically reduced activity of the 2–116 re-
pressor domain, while combined mutation of ZF 1 and 2
abolished activity (compare lanes 14–16 with lane 6).
A similar, but not identical, response to the mutations
was seen in the Vldlr context (Figure 6D). In this case,
more of the linker sequence was required for full activity
with progressively diminishing activity upon C-terminal
deletion into the linker (Figure 6D, lanes 5–9, Figure 6E).
Deletion of the second pair of zinc fingers (lane 5) or in-
ternal deletion of the C-terminal part of the linker (lane
4) had no effect on activity. As for repressor activity, the
linker sequence alone was inactive (lane 10), but in com-
bination with the second pair of zinc fingers the fusion
protein retained substantial activity (lane 11), albeit less
than the first pair (lane 5). This activity was reduced fur-
ther by removal of the N-terminal part of the linker
(lane 12) and abolished when only ZF34 remained (lane
13). Thus splicing activation is more dependent than re-
pression upon the full linker sequence (Figure 6E). Al-
though the activity of the 2-116 construct was already
diminished, we tested the importance of RNA binding.
Abrogating the RNA binding capacity of the 116 con-
struct led to a severe, albeit not total reduction in activ-
ity (Figure 6D, lanes 14–16 compared to 6).
We analysed RNA binding of some of the C-terminal
deletion fragments (Figure 5D-F). The miminal repressor
domain MBNL1-2-116 bound to the Vldlr and Tpm1
RNAs with affinity reduced compared to the complete N-
terminus but actually higher than the N-terminus with
point mutations in ZF34 (Figure 5D compared to 5A,B).
In addition, the 2–116 protein showed additional subse-
quent binding events on all three RNAs, consistent with
the fact that it has only 2 ZFs that can contact the RNA.
The 2–91 protein, which showed almost complete loss of
tethered activation activity (Figure 5D lanes 6–8) bound
to each RNA with affinity similar to 2–116 (Figure 5E),
emphasizing that RNA binding is necessary but not suffi-
cient for activity. Finally, the 2–72 protein, which lacks an
experimentally observed C-terminal extension to the ZF2
domain [12,13] failed to bind RNA at any concentration,
confirming the importance of the additional α-helix
(Figure 5F).
PTB associates with Vldlr RNA but does not regulate its
splicing
MBNL and PTB act as co-repressors of Tpm1 splicing
[22]. Pull-downs with biotinylated Vldlr RNA indicated
that PTB was one of the major binding proteins in HeLa
nuclear extract (data not shown). We therefore askedwhether PTB acted synergistically or antagonistically
with MBNL1 in the regulation of Vldlr splicing. As
shown earlier, overexpression of MBNL1 promoted skip-
ping of Tpm1 exon 3 but inclusion of the Vldlr exon
(Figure 7B, C lanes 1,2). Overexpression of PTB had lit-
tle effect on Tpm1 splicing (Figure 7C lane 3), as PTB is
not limiting in HeLa cells [29]. However, PTB/nPTB
knockdown led to decreased exon skipping (lanes 1
and 4). In contrast, Vldlr splicing was unresponsive to ei-
ther overexpression or knockdown of PTB (Figure 7C
lanes 1,3,4), suggesting that binding of PTB to Vldlr is
non-functional. Furthermore, the activating effect of
MBNL was not reduced upon PTB knockdown, and actu-
ally appeared to be slightly increased (Figure 7C lane 5).
Therefore, while MBNL1 and PTB cooperate to repress
Tpm1 splicing, MBNL1 acts independently to activate
Vldlr splicing, and PTB binding to Vldlr appears to be
non-functional.
Discussion
The data presented here, drawing upon point mutations
to impair RNA binding of ZF domains, deletion muta-
tions, and artificial MS2 tethering, provide insights into
the domains of MBNL1 that are involved in activation
and repression of splicing. Our results are complementary
to other published reports [16-18], and taken together the
different studies converge upon some common themes.
Among our key findings are the following. First, the N-
terminal region of MBNL1 encompassing the four ZF
domains is nearly fully active in most assays (Figure 2).
Second the C-terminal region is inactive in conventional
overexpression assays, but retains some activity in teth-
ered assays where the MS2 domain recruits it to target
RNAs (Figure 2). This residual activity might be associated
with the ability of the C-terminal region to mediate
dimerization [16,28], which might allow tethered C-
terminal to interact with intact endogenous MBNL pro-
teins, perhaps promoting their recruitment to the RNA.
Third, MBNL1 is remarkably tolerant of RNA binding
mutations to individual ZF domains (Figures 1, 3), consist-
ent with previous results [18]. Fourth, pair-wise inactiva-
tion of ZF12 was in most cases more deleterious than
inactivation of ZF34 (Figure 3). This is consistent with the
effects of deletions that remove ZF12 or ZF34 (Figure 6,
constructs 72–253 and 2–183 respectively), and with the
effects of the didomain point mutations upon RNA bind-
ing (Figure 5A-C). Fifth, both repression of the Tpm1
exon and activation of the Vldlr exon required not just an
intact ZF didomain, but also the linker sequence connect-
ing ZF2 and 3 (Figure 6). Finally, there were some differ-
ences in the responses of the repressed Tpm1 and the
activated Vldlr exons to different MBNL1 mutations. Acti-
vation of the Vldlr exon was more sensitive than repres-
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Lane : 1 2 3 4 5 6 7 8 9
Figure 7 PTB co-regulates Tpm1 but not Vldlr splicing. A. Western blots with anti-PTB (upper), anti-FLAG (middle) and anti-actin (lower panel).
Cells were treated with control C2 siRNA (lanes 1–6) or PTB/nPTB siRNAs (lanes 7–9). Lanes 4–1 show successive 2-fold dilutions of the C2 control
to allow assessment of knockdown. In lanes 6 and 9, FLAG-PTB was overexpressed; in lanes 5 and 8, FLAG-MBNL1 was overexpressed. B. The
Tpm1 ΔBP minigene was cotransfected with control C2 (lanes 1–3) or PTB/nPTB siRNAs (lanes 4–6). In addition, FLAG-PTB (lanes 3, 6) or FLAG-
MBNL1 (lanes 2, 5) were also cotransfected. C. The Vldlr minigene was cotransfected with control C2 (lanes 1–3) or PTB/nPTB siRNAs (lanes 4–6).
In addition, FLAG-PTB (lanes 3, 6) or FLAG-MBNL1 (lanes 2, 5) were also cotransfected.
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activated and repressed exons [16,17]. The minimal re-
pressor domain for MBNL1 when tethered encompasses
zinc fingers 1 and 2, with a region of further linker se-
quence up to amino acid 102. The minimal tethered acti-
vation domain comprises ZF1 and 2 and the full linker
sequence to amino acid 183. In contrast to the effects of
truncation mutations, effects of the ZF12 RNA binding
mutations were more pronounced upon Tpm1 than Vldlr.
The ZF12 mutation led to complete loss of activity upon
the Tpm1 exon, whereas with the Vldlr minigene this mu-
tation led to only a slight reduction in activity (Figure 3).
Likewise, within the context of the effector fragment 2-
116-MS2, mutation of ZF12 abolished repressor activity,
while retaining ~30% of activator activity (Figure 6). Thedifferential effects of MBNL1 mutations upon the Tpm1
and Vldlr exons are interesting. However, they cannot be
generalized for all activated or repressed targets of MBNL
proteins. Indeed, a systematic analysis of combined
MBNL1 ZF mutants with a panel of 6 MBNL regulated
events, showed that the relationship between ZF muta-
tions and effects upon activity upon different splicing sub-
strates is quite complex, with at least two classes of target,
each encompassing repressed and activated targets [18].
In agreement with our conclusions the same study showed
that MBNL activity upon Vldlr did not correlate well with
its RNA binding ability [18].
A surprising feature of our results is that the ZF RNA
binding mutations had a greater effect in the MS2 teth-
ering assays (Figure 3) than in the untethered assays
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teins would be less sensitive to mutations in their RNA
binding domains, since the MS2 domain should bypass
at least some of the RNA binding functions of the intact
protein. However, the C-terminal domain, which mediates
dimerization [16,28] and on its own has some activity in
the tethering assays (Figure 2), was missing in most of the
subsequent MS2-tethering assays (Figures 3, 6), which
might account for the greater sensitivity to the ZF muta-
tions. In addition to the RNA binding mutations of the ZF
domains, we also tested a set of mutations in ZF4 de-
signed to impair intra-molecular contacts formed between
MBNL molecules in crystal structures. Although previous
studies have implicated the variably spliced C-terminal re-
gion of MBNL in dimerization [16,28], it was possible that
the ZF4 mediated contacts might also be functional. How-
ever, these mutations had no functional effect in a number
of assays of MBNL1 activities (Figure 4). Although we did
not test the mutations in direct assays for dimerization,
the lack of effect in functional assays suggests that these
contacts are not physiologically relevant.
The deleterious effects of RNA binding mutations in a
tethered function assay is initially surprising, given that
the starting point of the assay is to bypass the normal
mode of RNA binding at a particular location. However,
this has been observed with similar studies of RbFOX [23]
and PTB [30], and provides insights into the possible
mechanisms of splicing regulation. Given that many RNA
binding proteins, including MBNL proteins, have multiple
RNA binding domains, it could be that the MS2 tether re-
places the role of a subset of the RNA binding domains,
and that functional effects require the remaining domains
to interact with RNA for one of a number of reasons. The
protein might need to bind to more than one site in the
target pre-mRNA to be functional, perhaps forming an
RNA architecture conducive to regulated exon skipping
or inclusion; the protein might have to interact with an-
other RNA; or the protein might have to interact with
RNA in order to interact with important partner proteins.
Taken in order, we already know that there are at least
two major MBNL1 binding sites flanking Tpm1 exon 3
[22,31]. We also identified additional YGCY motifs down-
stream of the Vldlr exon that mediate MBNL1 activity
(data not shown). Alternatively, the additional RNA inter-
actions could be with a distinct RNA species such as U1
snRNA; inhibition of the N1 exon of CSRC involves a
PTB-U1 snRNA interaction [32]. Finally, RNA binding
might be important to induce a conformation that facil-
itates interaction with co-regulatory proteins [22]. These
different explanations are not all mutually exclusive; for
example, a protein-RNA interaction might promote a
necessary RNP architecture as well as inducing a con-
formation change promoting necessary protein-protein
interactions.Analysis of the relationship between position of bind-
ing on RNA substrates and the mode of action as a re-
pressor or activator indicates that in general MBNL
binding upstream on an exon is associated with repres-
sion while downstream binding leads to activation
[10,33,34], similar to a number of other regulatory pro-
teins [4]. However, in the case of repression there are
also binding peaks downstream of the exon as well, sug-
gesting a sub-set of events which are regulated nega-
tively by MBNL sites flanking the exon. This suggests
the possibility of two discrete types of MBNL-repressed
event, which might operate in a mechanistically distinct
manner or might share some common mechanistic ele-
ments. In the first case, MBNL binding sites immediately
upstream of the regulated exon might be sufficient to
interfere with binding or activity of constitutive splicing
factors such as U2AF, as has been suggested in the
cTNT transcript [35,36]. In the case of exons such as
Tpm1 exon 3 the flanking sites might be necessary in
order for the upstream sites to effectively interfere with
3′ splice site recognition factors, perhaps by cooperative
binding of oligomers and consequent looping of inter-
vening RNA [37,38]. Alternatively the flanking regula-
tory sites might need to act in a concerted way on the 3′
and 5′ splice sites. The two tandem zinc finger arrays of
MBNL are arranged with each zinc finger ‘back-to-back’,
which would cause an anti-parallel alignment of a bound
RNA. It appears unlikely that a single MBNL1 protein
could bind to both the elements flanking Tpm1 exon 3.
Indeed, mutations in ZF12 and ZF34 have similar effects
upon binding to either the upstream or the downstream
Tpm1 element (Figure 5A-C). However, we have recently
shown that the minimal repressor region of MBNL inter-
acts with PTB protein, in an RNA-dependent manner
[22], and there are PTB sites flanking exon 3, with two to
three molecules binding either side [39]. Moreover MBNL
has been shown to interact with itself [16,28]. Taken to-
gether this suggests a complex forming across the exon,
with homotypic and heterotypic interactions between
MBNL and PTB molecules acting to stabilise a looped
structure which promotes exon skipping. Analysis of pro-
teins binding to the Vldlr substrate indicated strong inter-
action of PTB, suggesting that it might act as a
coactivator. However, overexpression and knockdown ex-
periments clearly showed that PTB played no role in regu-
lating Vldlr splicing (Figure 7). Indeed, we also found that
PTB-MS2 had no activity when tethered downstream
of the Vldlr exon, despite the fact that it can activate
its own target exons from this location [40]. This
clearly indicates that different activators have distinct
molecular targets, even when binding at similar loca-
tions. An important future line of work will be to
identify the molecular targets of the minimal MBNL1
activator domain.
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Constructs
The Tpm1 minigene reporters and Δbp mutation have been
described previously [22,27,31]. The Vldlr wildtype mini-
gene was a kind gift from Prof. Manny Ares (University of
California Santa Cruz) [10]. This minigene was mutagenized
to introduce a Pst1 site then an MS2 hairpin was inserted
using the following oligo: 5’-gAGGATCACCctgca-3’. Ex-
pression plasmids for MBNL1 N and C terminal trunca-
tions have been described previously [22]. Mutagenesis was





CC-3. MBNL1 truncations were cloned by inserting the
coding sequence for the relevant portion of MBNL1 into
the AvrII and MluI sites in the pCIMS2-NLS-FLAG vec-
tor [20,41]. Plasmids for bacterial expression were cloned
by insertion of appropriate coding sequence into the
pGEX-4-T3 vector. Sequences for expression of Tpm1 or
Vldlr RNA were cloned into pGEM-4Z plasmids (Pro-
mega), and transcribed usingT7 polymerase. Sequences










Cells were transfected a day after splitting to 105 – 2 ×
105 cells per well in a 6 well plate. Transfections were
performed using 400 ng effector construct unless other-
wise stated, with 200 ng reporter, made up to 1 μg with
empty pGEM4Z vector as necessary. Per well 1μg of
DNA, 100 μl Optimem and 2 μl Lipofectamine (Invitro-
gen 18324–012) was used. Lipofectamine-DNA mix was
incubated for 30min at room temperature, then diluted
to 1ml in Opti-MEM-1 and applied to cell monolayer
previously washed with PBS. Treated HeLa cells were in-
cubated for 5 hr at 37°C, and then the transfection mix
was replaced with 2 ml Dulbecco’s Modified Eagles
Medium (DMEM) supplemented with Glutamax & 10%
fetal bovine serum (FBS). Cells were then incubated for
a further 48 hours, then RNA and protein was harvested
from the cultures using Trizol reagent (invitrogen) or
boiled SDS loading buffer respectively.
For MBNL1 knockdown, the following target sequence
was used: 5’-AACACGGAAUGUAAAUUUGCA-3’ [42].
HeLa cells were split to a density of 2 × 105 in 1.7 mlDMEM +10% FBS medium in 6 well plates, and incu-
bated at 37°C for 24 hours. Each well was treated with
10 nM siRNA (THH2 siRNA for MBNL1 knockdown or
control C2 siRNA) and 15 μl Oligofectamine (Invitrogen
12252–011), diluted in 500 μl Optimem and incubated
prior at room temperature for 20 minutes. Cells were
then incubated for 24 hours at 37°C. After 24 hour incu-
bation DNA transfections were performed as above
using lipofectamine or lipofectamine 2000 reagent. Cells
were incubated for 5 hours at 37°C, then the medium on
them replaced with 1.5ml DMEM+10% FBS. To each well
10 nM siRNA and 3 μl Lipofectamine 2000 reagent in 500
μl Optimem was added, which had been pre-incubated for
20 minutes at room temperature. Cells were incubated for
a further 48 hours, then harvested.
RNA and protein analysis of transfections
For RNA analysis, cells in 6 well plates were washed
using twice with 2 ml PBS, then to each well 1 ml tri-
reagent (Sigma-Aldrich) was added, and purified accord-
ing to the manufacturers’ protocols. Samples were
DNAse I treated using 2 units of rDNAse (Ambion) in
10 mM Tris pH 7.5, 2.5 mM MgCl2, 0.5 mM CaCl2 for
30 minutes – 1 hour at 37°C, phenol extracted and etha-
nol precipitated. PCR analysis used the following primers
for Vldlr minigenes:
V4rt - 5’-GTGGCAAAGGTGCCCTTGAG-3’ - (rt primer)
V1 - 5’-ACGTGGATGAAGTTGGTGGT-3’ - (5’ primer)
V3 - 5’-GGCACCGAGCACTTTCTTGC-3’ - (3’ primer)
and the following primers for Tpm1 minigenes:





Reverse transcriptions were performed using 2–3 μg of
total RNA, and 100 ng of RT primer, in 50 mM Tris pH
6.3, 40 mM KCl, 8 mM MgCl2, 2 mM DTT. Samples
were heated for 15 minutes at 55°C, then cooled to 42°C,
and 2 μl 10 mM dNTP and 1 μl AMV-RT (Promega) en-
zyme added, and incubated at 42°C for 60 minutes. For
the PCR reaction, the 3’ primer was 5’ end labeled with
[32P]-ATP,. Oligo primer (4 pmoles per PCR reaction) was
incubated at 37°C for 60 minutes in 50 mM Tris 10 mM
MgCl2 T4 polynucleotide kinase enzyme (NEB) and 0.1 μl
[α-32P]-UTP per PCR reaction. After incubation the solu-
tion was phenol extracted, and purified on a G-50 spin
column (GE Healthcare). The labelled oligo was made up
to concentration of 1 pmole/μl. 2 μl of RT reaction was
taken into fresh eppendorf in buffer (50 μM KCl, 10 μM
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pmole of the reverse primer. Samples were heated to 92°C
for 3 minutes, then cooled to 80°C, and 0.25 μl Taq poly-
merase (Roche) and 10 pmol 32P-labeled probe added.
The samples were then cycled for 30 cycles of 94°C for 30
seconds, 62°C for 30 seconds and 72°C for 60 seconds.
RT-PCR products were analysed on denaturing 4% PAGE
gels, using Sequagel (National Diagnostics EC-833) sys-
tem. Samples were diluted in formamide loading buffer,
heated to 90°C for 5 minutes, then loaded. Gels were run
for 100 minutes at constant 38 W, the gel was dried and
exposed on phosphorimager casette (Molecular Dynam-
ics). The results were quantified using ImageQuant Soft-
ware (GE Healthcare) and analysed using Excel (Microsoft)
and Graphpad 5 (Prism Software). Statistical judgements
were made using either students t-tests or, where multiple
combinations tested, a post-ANOVATukey test, which is a
variation of the students t-test which aims to eliminate
type 2 errors stemming from multiple comparisons without
Bonferroni corrections. Statistical significance is indicated
by: ns, not significant; * P < 0.05; ** P < 0.01; ***, P < 0.001.
For protein analysis, the cell monolayer in 6 well plates
was washed twice with 2 ml PBS, then directly to each
well 150 μl of hot SDS buffer (pre-heated to 100°C for 5
minutes) was added. The cells were scrapped using
upturned P-1000 tips, extracted into eppendorf tubes,
and frozen on dry ice. Samples were heated again to
100°C for 5 minutes, separated using SDS-PAGE, ana-
lysed using standard western blotting techniques, and
imaged using standard ECL techniques. For western blot
analysis primary antibodies were in house anti-rabbit
MS2 or anti-FLAG from Sigma (F1804). Protein loading
was checked by Ponceau staining and, in some cases, by
re-probing with anti-actin antibodies.
Recombinant protein expression
Recombinant MBNL1 protein was expressed and puri-
fied from E.coli BL21 cells. 400 ml cultures were induced
at OD600 = 0.5 by the addition of 1 mM IPTG, and
grown for 3 hours shaking at 225 rpm. The cultures
were then pelleted, washed in MTPBS (150 mM NaCl,
16 mM Na2HPO4, 4 mM NaH2PO4, pH 7.3) and lysed
using a French Press (Stansted Fluid Power) according
to the manufacturer’s instructions. The homogenised
samples were centrifuged at 7741 rcf, 4°C, for 10 mi-
nutes. Samples were then purified using GST Sepharose
4B beads (GE Healthcare) according to manufacturers
protocols. Briefly - the beads were pre-washed with 5–
10 volumes of water, MTPBS and MTPBS + 1% Triton-
X100. To the homogenised sample Triton-X100 added
to concentration of 1%. This bacterial homogenate was
then incubated with the GST beads at 4°C, for 1 hour.
The beads were washed 4 times with 2.5 volumes of
MPTBS + 1% Triton-X100, then loaded into a disposablebiorad column at 4°C. The recombinant proteins were
eluted from the column using 3×800 μl of 25 mM re-
duced glutathione in 100 mM HEPES (pH 8.9), followed
by 3×800 μl of 50 mM reduced glutathione in 100 mM
HEPES. All fractions of interest were pooled, and dia-
lysed in 1.8 litres of Dignam Buffer E overnight at 4°C
using Slide-A-Lyzer Dialysis Cassettes (Thermo Scien-
tific), according to manufacturer’s protocols. The con-
centration of the recombinant proteins was estimated
with reference to BSA standards.
Electrophoretic-mobility shift and UV crosslinking assay
High specific activity [α-P32] UTP labelled RNAs were
made using standard protocols with either SP6 or T7
polymerase. Binding reactions were set up in microtitre
plates (Corning) pre-lined with BSA. Mobility shift as-
says had a total 5 μl reaction volume, with 10 fmol
RNA, 20 μg/ml rRNA, 10 mM HEPES pH 7.9, 10 μM
ZnCl2, 3 mM MgCl2, 5% Glycerol, 1 mM DTT, and pro-
teins at appropriate concentration. The reaction was in-
cubated for 15 minutes at 30°C, then 0.5 μl of a 55 mg/ml
Heparin (Sigma) added, and the samples incubated for a
further 5 minutes. Before loading onto the gel 1 μl of
50% glycerol was added. 5% poly-acrylamide gels were
used, with 30:1 bis:acrylamide ratio. Gels were run at
200 volts for ~ 2hr, 4°C after pre-running for 1–2 hours,
at 200 volts. Dried gels were analysed by phosphor-
imager (Molecular Dynamics). After scanning on Ty-
phoon scanner results were analysed using ImageQuant
(GE Healthcare) and Photoshop (Adobe). Dissociation
constants were estimated from the total protein concen-
tration that produced 50% binding. For UV crosslinking,
the total reaction volume was 10 μl. After addition of
heparin, samples were subjected to 19200 J.cm-2 UV light,
followed by digestion with 50 μg RNase A and 140 U
RNase T1. Samples were then separated by SDS gel elec-
trophoresis and dried gels analyzed by phosphorimager.
Conclusions
Our results highlight the common and distinct domain
requirements for activation or repression of splicing by
MBNL1. Full length MBNL1 is relatively insensitive to
inactivating mutations of individual ZF domains. How-
ever, when the protein is recruited to RNA by tethering
with a heterologous RNA binding domain and deletion
mutations are introduced, the dependency on functional
ZF domains becomes more acute. Full tethered repressor
and activator functions require ZF domains 1 and 2 that
are able to bind RNA, suggesting that both types of ac-
tivity require multivalent interactions with RNA. How-
ever, the ZF domains alone are insufficient for activity.
Additional regions of the linker separating ZF domains 2
and 3 are required for splicing activity but not RNA
binding. The additional regions differ for repression or
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quired for full activation. This suggests the involvement
of different sets of interacting cofactors for activation or
repression of splicing by MBNL1.
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